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ABSTRACT
This comprehensive review summarizes the
mechanism of action, pharmacokinetics,
efficacy, and safety of besifloxacin ophthalmic
suspension, 0.6% and examines its role in the
treatment of ocular surface bacterial infections.
Besifloxacin possesses balanced activity against
bacterial topoisomerase II (also called DNA
gyrase) and topoisomerase IV. It has shown a
low potential to select for bacterial resistance
in vitro and demonstrated strong in vitro activity
against many Gram-positive, Gram-negative,
and anaerobic organisms, including
methicillin-resistant Staphylococcus aureus and
Staphylococcus epidermidis (MRSA and MRSE,
respectively). Ocular pharmacokinetic studies
have shown that besifloxacin achieves high,
sustained concentrations in the tear fluid and
conjunctiva following topical administration,
with negligible systemic exposure. Large
randomized, controlled clinical trials have
established the efficacy and safety of
besifloxacin administered three times daily for
5 days for treatment of acute bacterial
conjunctivitis in both adults and children, with
high rates of clinical resolution (up tomore than
70% by day 5) and bacterial eradication (more
than 90% by day 5), and a low incidence of
adverse events. Additionally, besifloxacin
applied twice daily for 3 days demonstrated
greater efficacy than vehicle in treating
bacterial conjunctivitis. Case reports, a large
retrospective chart review, and animal studies
have provided supporting evidence for the
efficacy of besifloxacin in the management of
acute bacterial keratitis. There is some evidence
to suggest that besifloxacin may provide an
advantage over other current-generation
fluoroquinolones in antimicrobial prophylaxis
for ocular surgery. Besifloxacin is an appropriate
option for treatment of bacterial conjunctivitis,
and its use in the treatment of bacterial keratitis
and lid disorders, as well as for surgical
prophylaxis, appears promising and warrants
further evaluation.
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INTRODUCTION
Fluoroquinolones (FQs) have been successfully
used in ophthalmology for nearly two decades,
thanks in large part to a series of incremental
improvements in their antimicrobial activity
and pharmacokinetic profiles [1]. Today,
treatment for bacterial ocular surface
infections—including conjunctivitis,
blepharitis, and keratitis—is largely empirical;
the FQs’ broad-spectrum antimicrobial activity
and documented safety and lack of toxicity
make them well suited to empirical therapy
[2–4]. With activity against a broad spectrum of
bacterial pathogens including Gram-positive,
Gram-negative and anaerobic organisms [1, 5],
current-generation FQs, such as gatifloxacin,
moxifloxacin, and besifloxacin, have become
first-line agents for the treatment and
prevention of bacterial ocular infections [6, 7].
As with other antibiotics, resistance to FQs has
developed [2, 8]. Until the early 2000s, FQ
resistance was uncommon among ocular
pathogens, but with the rapid increase in clinical
utilization of FQs (both systemic and topical),
resistance has begun to emerge [8]. Surveillance
studies have shown an alarming trend of
increasing resistance in ocular isolates over the
past twodecades [9–14].Mostnotably,pathogenic
strains such asmethicillin-resistant Staphylococcus
aureus (MRSA) and methicillin-resistant
Staphylococcus epidermidis (MRSE) are becoming
prevalent, and many strains show multidrug
resistance including resistance to both earlier
and current generation FQs.
The most recent addition to the topical
ocular FQ family is besifloxacin, an FQ
developed solely for topical ophthalmic use. A
0.6% besifloxacin ophthalmic suspension
(Besivance, Bausch ? Lomb, Rochester, NY,
USA) was approved in the US and Canada for
the treatment of bacterial conjunctivitis in
2009 [15, 16]. The first topical
chlorofluoroquinolone, besifloxacin has a
unique molecular structure designed to confer
increased antibacterial potency [4, 17]. In
susceptibility assays, besifloxacin demonstrated
potent in vitro activity against a wide range of
pathogens, including those that are resistant to
other FQs and antibacterial classes [5].
Perhaps the most distinctive feature of
besifloxacin is its lack of a systemic
formulation. Unlike all other ophthalmic FQs,
besifloxacin has never been used systemically,
nor has it been used in agriculture or animal
husbandry [2]. Because extensive systemic
antibiotic use and antibiotic use in agriculture
are two major drivers of resistance development
among bacteria [18–20], it has been suggested
that the limitation to ocular use may slow the
development of bacterial resistance to
besifloxacin, although cross-resistance from
other FQs is still possible [8].
This article reviews our current knowledge
of besifloxacin, looking at mechanisms of
action, pharmacokinetic properties, in vitro
antimicrobial activity, and, most importantly,
clinical efficacy and safety. The goal is to review
and evaluate besifloxacin’s current and
potential roles in treatment and prevention of
ocular surface bacterial diseases.
METHODS
A literature search was conducted in October
2015 of the Medline, Biosis Previews, and
Embase databases, employing ‘‘besifloxacin’’ or
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‘‘Besivance’’ as the search terms. The search was
limited to English-language articles, and 156
papers/abstracts were retrieved. Primary articles,
review articles, and abstracts on the mechanism
of action, pharmacokinetic properties, or
clinical efficacy and safety of besifloxacin were
identified (n = 52), and additional relevant
articles were collected from the references of
selected publications. This article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
RESULTS AND DISCUSSION
Mechanism of Action
FQs act by inhibiting two enzymes essential for
bacterial DNA synthesis: topoisomerase II (DNA
gyrase) and topoisomerase IV [21, 22].
Topoisomerase II relaxes supercoils of
double-stranded bacterial DNA to facilitate
DNA replication; topoisomerase IV is
responsible for unlinking daughter
chromosomes to allow their segregation into
two daughter cells at the end of each round of
replication, an action known as decatenation.
Binding with these DNA-tethered enzymes to
form FQ–enzyme–DNA complexes, the FQs
exert their effect by inhibiting the
topoisomerases, blocking DNA replication,
and, ultimately, killing the bacterial cell [6, 22].
Older FQs, such as ofloxacin and
ciprofloxacin, preferentially bind one of the
essential enzymes [6]. In most Gram-negative
bacteria, topoisomerase II tends to be the
primary target; in Gram-positive organisms,
the primary target is typically topoisomerase
IV [6, 23]. However, newer agents, such as
gatifloxacin and moxifloxacin, are believed to
possess dual activity, with more comparable
targeting activity against both topoisomerases
[6, 24]. This dual-binding mechanism of action
increases antimicrobial activity, particularly
activity against Gram-positive pathogens [6].
Additionally, potent inhibition of both
topoisomerases is thought to reduce
spontaneous emergence of resistance, as two
point mutations are needed in the enzymes to
confer resistance to the FQ, and double
mutations, as a genetic event, rarely occur [25,
26].
Besifloxacin, the newest ophthalmic FQ,
likewise targets both enzymes but has been
shown to act through potent, balanced
inhibition of both topoisomerase II and
topoisomerases IV [27]. Results of enzymatic
activity assays by Cambau et al. [27] suggested
that, in S. pneumoniae, besifloxacin has greater
in vitro activity against topoisomerase II and IV
than moxifloxacin or ciprofloxacin. The 50%
inhibitory concentration (IC50) of besifloxacin
against S. pneumoniae topoisomerase II was four-
to eightfold lower than that of moxifloxacin
and 15-fold lower than that of ciprofloxacin.
Against S. pneumoniae topoisomerase IV, the
concentration of besifloxacin required to
inhibit 50% of isolates was two- and fivefold
lower than moxifloxacin and ciprofloxacin,
respectively. Consistent with the idea that
balanced dual activity against the essential
bacterial enzymes reduces the emergence of
bacterial resistance, besifloxacin-resistant
S. aureus and S. pneumoniae mutants emerged
in vitro at rates nearly two orders of magnitude
lower than those of mutants resistant to
ciprofloxacin [27], which primarily targets
topoisomerase IV in Gram-positive bacteria
[6, 27].
Beyond its antimicrobial activity,
besifloxacin might provide anti-inflammatory
efficacy in ocular infections [28, 29]. Zhang
et al. observed inhibitory effects on synthesis of
pro-inflammatory cytokines with besifloxacin
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in ocular and nonocular cells exposed to
stimulants such as interleukin-1b and
lipopolysaccharide [28, 29]. This ability to
attenuate inflammatory cytokine responses in
stimulated cells has also been found in other
FQs [30].
Antibacterial Activity
Progress from one FQ generation to the next
was primarily driven by structural modification
to the quinolone backbone in an effort to
produce broadened and enhanced bactericidal
activity, primarily activity against
Gram-positive aerobes and anaerobic
organisms [1, 23, 31, 32] (Fig. 1). Nalidixic
acid, the first quinolone antibiotic and the one
from which FQs were subsequently derived, has
very low activity against aerobic Gram-positive
organisms. Early FQ compounds first achieved
added activity against Gram-positive
staphylococci from the addition of a fluorine
at C-6 (hence the name FQs) and a cyclic
diamine piperazine at C-7 of the quinolone
nucleus. Later, the addition of a cyclopropyl
side chain at position N-1, as in ciprofloxacin,
yielded a wider spectrum of activity against
both Gram-positive and Gram-negative aerobes.
The current generation FQs, including
gatifloxacin and moxifloxacin, have a
methoxy substituent at the C-8 position and,
consequently, additional activity against
Gram-positive and anaerobic bacteria [6, 33].
The besifloxacin molecule (Fig. 2) has a
chemical structure similar to gatifloxacin and
moxifloxacin but differs in that it has a chlorine
atom at the C-8 position (replacing the C-8
methoxy group in moxifloxacin and
gatifloxacin) and an amino-azepinyl group at
the C-7 position (replacing the
pyrrolol–pyridinyl and methyl–piperazinyl
substituents in moxifloxacin and gatifloxacin,
respectively) [4]. It is this unique combination
of 8-chloro and 7-azepinyl substituents, rather
than either moiety alone, that is believed to be
responsible for besifloxacin’s improved
Fig. 1 Structural evolution of ﬂuoroquinolones
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antibacterial potency compared with other
current generation FQs [4].
Haas et al. [5] evaluated besifloxacin’s
in vitro activity using 2690 bacterial clinical
isolates of 40 species, collected in the US from
ocular and respiratory specimens between 2005
and 2008. Consistent with its relatively
balanced dual targeting of topoisomerase II
and topoisomerase IV [27], minimum
inhibitory concentration (MIC) values showed
besifloxacin to be active against a broad
spectrum of Gram-positive, Gram-negative,
and anaerobic organisms, including those
commonly associated with ocular infections:
S. aureus, S. epidermidis, S. pneumoniae, and
Haemophilus influenzae [5]. Among various
topical agents commonly used for the
treatment of ocular infections—including
moxifloxacin, gatifloxacin, azithromycin, and
tobramycin—besifloxacin had the best in vitro
activity (lowest MICs) against Gram-positive
pathogens and anaerobes and equivalent or
better activity against most Gram-negative
isolates [5]. In particular, besifloxacin
displayed better activity against resistant
strains, including MRSA and
ciprofloxacin-nonsusceptible staphylococci,
and activity equal to or better than that of
other tested FQs against
ciprofloxacin-nonsusceptible Pseudomonas
aeruginosa isolates.
The activity profile of besifloxacin was
confirmed by Haas et al. [34] in an integrated
analysis of microbial data from three
besifloxacin clinical trials. Across the three
trials, a total of 1324 bacterial conjunctivitis
isolates, representing more than 70 species,
were obtained from patients in the US and
Asia. Results from in vitro MIC testing showed
that, overall, besifloxacin (0.06 lg/mL for MIC50
and 0.25 lg/mL for MIC90, against all isolates)
was more potent than comparator FQs
(0.125–0.5 lg/mL for MIC50 and 0.5–2 lg/mL
for MIC90, against all isolates). While the
besifloxacin MIC90 against Gram-negative
organisms was 0.5 lg/mL compared to 0.125
and 0.25 lg/mL for the other FQs tested,
besifloxacin was the most potent agent tested
against Gram-positive pathogens, including
organisms resistant to other FQs. Against
ciprofloxacin-resistant MRSA and MRSE,
besifloxacin had 16- to 128-fold and 8- to
64-fold greater activity, respectively, in
comparison with other tested FQs.
Miller et al. [35] observed similar results in
comparing the in vitro efficacy of besifloxacin
and comparator antibiotics against 243 ocular
staphylococcal isolates collected from a variety
of ocular surface and intraocular infections
between 2003 and 2008. Besifloxacin was the
most potent FQ tested, with an MIC90 (4 lg/mL)
eightfold lower than that for moxifloxacin and
16-fold lower than that for ciprofloxacin. Of
note, besifloxacin maintained a relatively high
potency against staphylococci that were both
ciprofloxacin and methicillin resistant, with an
MIC90 of 4 lg/mL for ciprofloxacin-resistant
MRSA and 8 lg/mL for ciprofloxacin-resistant
MRSE.
Fig. 2 Chemical structure of besiﬂoxacin (7-[(3R)-3-
aminohexahydro-1H-azepin-1-yl]-8-chloro-1-cyclopropyl-
6-ﬂuoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid)
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Complementing these in vitro efficacy
findings, Haas et al. [36, 37] demonstrated
besifloxacin’s rapid bactericidal effect on
four major ocular pathogens—S. aureus,
S. epidermidis, S. pneumoniae, and
H. influenzae—using minimum bactericidal
concentration (MBC)/MIC and time-kill assays.
The MBC/MIC ratios of besifloxacin were B4 for
97.5% of all isolates tested (n = 120) [36]. For
the Gram-positive pathogens, in particular,
besifloxacin had the lowest MIC90 (0.06–4 mg/
L) and MBC90 (0.12–4 mg/L) of all agents tested,
which included not just FQs but also select
beta-lactams, macrolides, and aminoglycosides.
Regardless of the resistance phenotype of the
isolates, besifloxacin was bactericidal within
45–120 min, at least 2- to 4-times faster than,
and at lower concentrations than, gatifloxacin
or moxifloxacin [37].
It is noteworthy that all of the previously
mentioned besifloxacin studies documented a
high potency and bactericidal activity against
resistant organisms. This is further supported by
the five-year results of the Antibiotic Resistance
Monitoring in Ocular MicRoorganisms
(ARMOR) study, a nationwide bacterial
resistance ocular surveillance study initiated in
2009 to determine the susceptibility and
resistance profiles of S. aureus,
coagulase-negative staphylococci (CoNS),
S. pneumoniae, H. influenzae, and P. aeruginosa
isolates from ocular infections [14]. From 2009
through 2013, more than 3000 isolates were
contributed by 72 eye care centers, community
hospitals, and academic or university hospitals
across the US. The MIC results for these isolates,
particularly the staphylococci, showed a
significant level of antibiotic resistance:
methicillin/oxacillin-resistant strains
accounted for 42.2% and 49.7% of S. aureus
and CoNS isolates, respectively, and multidrug
resistance (defined as C3 antibiotic classes) was
prevalent among these methicillin-resistant
strains (86.8% for MRSA and 77.3% for
methicillin-resistant CoNS). Among the FQs
tested, besifloxacin demonstrated the greatest
in vitro potency against staphylococcal isolates,
especially the methicillin-resistant strains. Its
MIC90 against MRSA (2 lg/mL) and
methicillin-resistant CoNS (4 lg/mL) were
comparable to those of vancomycin (1 and
2 lg/mL, respectively).
Bacterial resistance to FQs arises primarily
from mutations in bacterial topoisomerase II
and topoisomerase IV genes [38, 39]. That
besifloxacin demonstrated greater potency
against FQ-resistant strains suggests that
besifloxacin is less affected by topoisomerase
mutations compared with older FQs. A previous
study demonstrated that, as the number of
mutations in genes encoding DNA gyrase and
topoisomerase IV increases, MIC values increase
for all tested FQs (besifloxacin, moxifloxacin,
gatifloxacin, ciprofloxacin, and levofloxacin);
the magnitude of this increase for besifloxacin,
however, was the smallest (128-fold between
susceptible and the most resistant strains)
compared to all other FQs (1024- to 2048-fold)
[40]. Drug efflux pumps may contribute to
antibiotic resistance in both Gram-positive
and Gram-negative organisms [41]. However,
this mechanism of resistance does not appear to
have a significant effect on susceptibility to
newer FQs, including besifloxacin [40, 42].
Pharmacokinetic Properties
Pharmacokinetic properties are important to a
drug’s in vivo efficacy. In a preclinical study in
New Zealand Composite rabbits, Ward et al. [17]
observed a concentration gradient in
compartments from the tear film to the blood
plasma following topical administration of a
single dose of besifloxacin ophthalmic
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suspension 0.6%. The mean ocular residence
times were longer than 7 h. Besifloxacin also
demonstrated rapid ocular penetration and
sustained retention in Dutch-belted rabbits
and two monkey species, with peak
concentrations observed within a half hour
and measurable levels detected in anterior
ocular tissues at all time points through 24 h
after a single administration [43, 44]. Proksch
et al. [43, 45] assessed ocular pharmacokinetics
of besifloxacin in tears of 64 healthy human
subjects in a single-center, open-label study
(Table 1). Maximum mean besifloxacin
concentration in the tear fluid was 610 lg/g at
10 min after a single topical administration.
Tear concentrations of 10 lg/g and higher were
sustained through 12 h and 1.60 lg/g and
higher through 24 h, well above the MIC90 for
major ocular pathogens, such as S. pneumoniae,
S. aureus, S. epidermidis, and H. influenzae [5].
The elimination half-life of besifloxacin in
human tears was estimated to be 3.4 h.
The commercially available besifloxacin 0.6%
ophthalmic suspension is formulated with a
mucoadhesive polymer (DuraSite, InSite
Vision Inc., Alameda, CA, USA) that enhances
drug retention on the ocular surface [46].
Extended contact time implies that high drug
concentrations are retained at the site of
infection; for concentration-dependent
antibiotics such as FQs, higher drug
concentrations mean greater microbial
eradication rates. Proksch et al. [47] determined
and compared the ocular pharmacokinetics of
besifloxacin, moxifloxacin, and gatifloxacin in
rabbits using the commercial formulations of
each drug. When compared tomoxifloxacin and
gatifloxacin, a single instillation of besifloxacin
(50 lL) resulted in noticeably higher
concentrations and prolonged retention of
besifloxacin on the ocular surface, with
concentrations of 90 lg/g or higher sustained
in tears through 8 h after dosing. With regard to
area under the curve during 24 h (AUC0–24)/
MIC90 ratio, a parameter widely used to predict
the clinical efficacy of FQs, a single dose of
besifloxacin achieved values of about 800 in
tears when tested against ciprofloxacin-resistant
MRSE and ciprofloxacin-resistant MRSA, far
exceeding the target level of C30–50 for
effective killing of Gram-positive bacteria [47].
By comparison, the AUC0–24/MIC90 ratios were
below 10 for bothmoxifloxacin and gatifloxacin.
In a comparative study evaluating
conjunctival drug concentrations of
besifloxacin, moxifloxacin, and gatifloxacin
after use of commercial topical FQ
formulations in humans, besifloxacin achieved
the greatest AUC0–24/MIC90 ratio for resistant
and non-resistant staphylococcal strains [48].
Results from this single-center, randomized,
double-masked, active-controlled study of 108
healthy volunteers demonstrated that
conjunctival concentrations of besifloxacin
exceeded the MIC90 against of
methicillin-susceptible S. aureus (MSSA) and
S. epidermidis (MSSE) for at least 2 h after a
single instillation. Mean residence time in the
Table 1 Pharmacokinetic parameters for besiﬂoxacin
0.6% in human tears after a single instillation
Parameter Value
Cmax, mean ± SD 610 ± 540 lg/mL
Tmax 10 min
AUC0–24h 1232 lg h/g
Elimination half-life 3.4 h
Systemic Cmax* \0.5 ng/mL
AUC0–24h area under the curve during 24 h, Cmax
maximum concentration observed, SD standard
deviation, Tmax time at which maximum concentration
is observed
* Measured in patients with bacterial conjunctivitis
following three times daily dosing [43]
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conjunctiva for besifloxacin was 4.7 h, the
longest among the FQs assessed (3.0 h for
moxifloxacin; 2.9 h for gatifloxacin).
Several studies have investigated anterior
chamber penetration of besifloxacin and other
FQs after topical ocular application. In contrast
to high ocular surface concentrations, topical
administration of FQs generally results in low
intraocular levels. A parallel, double-masked
clinical trial by Yoshida et al. [49] randomized
50 cataract surgery patients to receive
besifloxacin or moxifloxacin. Thirty minutes
after repeated preoperative instillation (4 drops,
once every 10 min), the mean aqueous
concentration of besifloxacin was 0.03 lg/mL,
while that of moxifloxacin was 1.61 lg/mL.
Thus, when compared with the MIC90 values
for S. epidermidis and S. aureus, neither of the
FQs achieved meaningful aqueous humor levels
[50]. Donnenfeld et al. [51] assessed aqueous
humor concentrations of besifloxacin,
moxifloxacin, and gatifloxacin 1 h following
topical instillation of a single drop of each drug
in 105 patients undergoing uncomplicated
cataract surgery. Mean aqueous humor
concentrations for besifloxacin, moxifloxacin,
and gatifloxacin were 0.13, 0.67, and 0.13 lg/
mL, respectively, well below the MIC90 of these
agents against methicillin-resistant and
ciprofloxacin-resistant S. epidermidis and
S. aureus isolates. Evans et al. compared the
aqueous penetration of besifloxacin and
moxifloxacin applied 4 times daily for 3 days
and 1 drop at 6, 4, 2, and 1 h prior to surgery in
a randomized, parallel-group study of 120
cataract surgery patients [52]. Mean
penetration levels for besifloxacin and
moxifloxacin, respectively, were 0.049 and
0.489 lg/mL at 1 h and 0.047 and 0.329 lg/mL
at 6 h.
Chung et al. [53] compared the intraocular
penetration of FQs after topical instillation into
rabbit eyes. The mean maximum
concentrations of besifloxacin, moxifloxacin,
gatifloxacin, and levofloxacin following single
instillation were reported to be 1.13, 10.15,
3.33, and 10.67 lg/g in the cornea, 3.70, 1.56,
0.95, and 1.99 lg/g in the bulbar conjunctiva,
and 0.11, 1.86, 0.64, and 2.24 lg/g in the
aqueous humor, respectively [53]. At 1 h
following repeated instillation (4 times, every
15 min), the FQs’ respective peak
concentrations were 1.91, 13.69, 6.99, and
22.60 lg/g in the cornea, 2.09, 1.48, 0.78, and
4.51 lg/g in the bulbar conjunctiva, and 0.19,
2.47, 1.29, and 5.52 lg/g in the aqueous humor.
Repeated instillation (4 times at 15-min
intervals) of besifloxacin resulted in an average
of 1.3 times higher concentrations of
besifloxacin in ocular tissues (bulbar
conjunctiva, cornea, aqueous humor, and
anterior vitreous), the smallest increase among
all FQs assessed (2.1 times on average) [53]. The
authors attributed this ‘‘surface-retentive’’
nature of besifloxacin to its DuraSite vehicle
and concluded that besifloxacin has favorable
pharmacokinetic properties for the treatment of
bacterial conjunctivitis and superficial bacterial
keratitis.
Efficacy Profile
Besifloxacin ophthalmic suspension 0.6% is
currently indicated for the treatment of
bacterial conjunctivitis caused by susceptible
organisms [15]. It has also been evaluated for
the treatment of bacterial keratitis, prophylaxis
of postsurgical infections, and treatment of lid
disorders but is not currently indicated for those
uses.
Bacterial Conjunctivitis
Acute bacterial conjunctivitis is normally a
self-limiting condition, but topical antibiotic
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therapy can speed clinical and microbiological
resolution, reduce the severity of the infection,
and lower the risk of complications such as
keratitis [54, 55].
The clinical and microbiological efficacy of
besifloxacin administered 3 times daily for
5 days for the treatment of bacterial
conjunctivitis was established in three
randomized, double-masked, controlled
clinical trials. Two compared besifloxacin with
its vehicle [56, 57], and one compared
besifloxacin with moxifloxacin [58]. A fourth
randomized, vehicle-controlled clinical study
evaluated the efficacy of besifloxacin 0.6%
administered twice daily for 3 days in the
treatment of bacterial conjunctivitis [59]. In all
four trials, clinical resolution (defined as the
absence of conjunctival discharge and bulbar
conjunctival injection) and bacterial
eradication (defined as absence of ocular
bacterial species present or above threshold at
baseline) were measured at similar time points
(day 5 ± 1 or day 8/9). The results are
summarized in Table 2.
Karpecki et al. [56] compared besifloxacin
with its vehicle in a multicenter phase II study
of 269 patients with acute bacterial
conjunctivitis, of which 118 were
culture-confirmed. The besifloxacin group
demonstrated better clinical and
microbiological outcomes at day 8 or 9
(P\0.001) compared with the vehicle group
(Table 2). The most commonly isolated bacterial
species in this study were H. influenzae (31.7%),
S. pneumoniae (27.6%), S. aureus (13.8%), and
S. epidermidis (4.8%). Besifloxacin showed high
rates of eradication of each of these species at
day 4 ± 1, in agreement with its low MIC90
(0.06–0.25 lg/mL) against these pathogens.
Tepedino et al. [57] reported similar efficacy
results from a vehicle-controlled phase III study
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conjunctivitis at 58 sites in the US. In the 390
patients with culture-confirmed acute bacterial
conjunctivitis, besifloxacin achieved
significantly better clinical and microbiological
outcomes at both analysis time points (day
5 ± 1; day 8 or 9) compared with vehicle
(Table 2).
A third multicenter phase III clinical trial was
conducted in the US and Asia to evaluate and
compare the clinical and antimicrobial efficacy
of besifloxacin 0.6% and moxifloxacin 0.5%
(Vigamox; Alcon, Fort Worth, TX, USA) [58,
60]. The study randomized 1161 patients, of
whom 533 had culture-confirmed acute
bacterial conjunctivitis. The two antibiotic
treatments produced comparable clinical and
microbiological outcomes on both days five and
eight (P[0.05; Table 2). In the group of
patients with S. aureus infection, the rate of
clinical resolution on day 8 was significantly
higher with besifloxacin treatment compared
with moxifloxacin (84.5% vs. 70.2%,
P = 0.0291).
A post hoc analysis of data from 815
pediatric patients (447 with culture-confirmed
bacterial conjunctivitis) who had participated
in the three clinical trials confirmed that
besifloxacin maintained its clinical and
antimicrobial efficacy in children and
adolescents (1–17 years of age) [61]. In a
multicenter, randomized study of 33 neonatal
patients (B31 days of age) with presumed
bacterial conjunctivitis, besifloxacin 0.6% and
gatifloxacin 0.3% given three times daily for
seven days demonstrated similar efficacy, with
high rates of clinical resolution (over 70%) and
microbial eradication (about 90%) for both
groups on day 8 or 9 [62].
DeLeon et al. [59] evaluated besifloxacin
administered twice daily for 3 days compared
with vehicle in 474 patients with bacterial
conjunctivitis (276 were culture-confirmed). At
day 4 or 5, both clinical and microbiological
outcomes were significantly better (P\0.001)
in the besifloxacin group than in the vehicle
group (Table 2). At day 7 ± 1, 4 days after
treatment discontinuation, rates of bacterial
eradication remained greater in the
besifloxacin group (P\0.001), whereas rates of
clinical resolution were not different
(P = 0.209).
In addition to its efficacy against the
common bacterial pathogens involved in
conjunctivitis, besifloxacin 0.6% has
demonstrated efficacy against less frequently
encountered species. P. aeruginosa, a
Gram-negative bacterium notorious for its
ability to cause severe keratitis, and which
accounts for about 5% of bacterial
conjunctivitis cases and up to one-third of
bacterial keratitis infections [12, 63]. Turaka
et al. [64] described a single case of giant fornix
syndrome associated chronic conjunctivitis that
was caused by P. aeruginosa and successfully
treated with besifloxacin. Silverstein et al. [65]
performed a post hoc analysis of clinical
outcomes in patients with bacterial
conjunctivitis due to P. aeruginosa across all
four aforementioned besifloxacin clinical
studies. Of 1317 patients with
culture-confirmed bacterial conjunctivitis, 9
patients (0.7%) with P. aeruginosa infection
were identified, and 5 of these received
besifloxacin. Bacterial eradication was achieved
in all five patients by the first follow-up visit
and clinical resolution was observed in four
patients by the second visit. The MIC90 for
besifloxacin against all P. aeruginosa isolates was
2 lg/mL, well below reported mean
concentrations of besifloxacin in human tears
following a single topical ocular administration
(610 lg/g at 10 min and above 10 lg/g through
12 h) [43]. On the basis of the bacterial
eradication and clinical resolution data, a
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revision of the original US Food and Drug
Administration (FDA)-approved labeling for
besifloxacin was made in 2012 to include
P. aeruginosa as an indicated bacterial pathogen
[15].
Using the same integrated data set, the
researchers also assessed the clinical efficacy of
besifloxacin 0.6% in conjunctivitis cases caused
by Serratia marcescens, Neisseria spp., MRSA, and
MRSE [66]. Treatment with besifloxacin resulted
in high bacterial eradication rates in all treated
infections: 100% by the first follow-up visit for
S. marcescens (n = 4) and Neisseria spp.
infections (n = 7) and 87.8% by the second
follow-up visit for infections caused by MRSA
(n = 12) and MRSE (n = 37). The MIC90 for
besifloxacin was 1 lg/mL for S. marcescens,
0.25 lg/mL for Neisseria spp., 0.06 lg/mL for
both ciprofloxacin-sensitive MRSA and
ciprofloxacin-sensitive MRSE, and 4 lg/mL for
both ciprofloxacin-resistant MRSA and
ciprofloxacin-resistant MRSE. The proportion
of patients with clinical resolution was 100%
(7/7) for Neisseria spp. infections and 75% (3/4)
for S. marcescens infections at the second
follow-up visit. For staphylococcal infections,
the rate of clinical resolution at the
first follow-up visit was 1/2 for
ciprofloxacin-sensitive MRSA, 2/10 for
ciprofloxacin-resistant MRSA, 15/21 for
ciprofloxacin-sensitive MRSE, and 6/16 for
ciprofloxacin-resistant MRSE; at the second
follow-up visit, the respective rates were 1/2,
5/10, 18/21, and 12/16.
Bacterial Keratitis
The clinical efficacy of besifloxacin 0.6% in the
treatment of bacterial keratitis has not been
evaluated in randomized, controlled studies.
Michaud reported a case of a patient with
contact lens-related severe keratitis that was
successfully treated with a regimen that
included besifloxacin 0.6% [67]. Pandit [68]
described a case of a patient with a large
corneal ulcer due to Brevundimonas diminuta.
Following months of treatment with a regimen
of multiple topical antibiotic agents, including
besifloxacin, the ulcer resolved leaving a
minimal corneal scar. A retrospective
chart review by Schechter et al. of more than
200 patients with bacterial keratitis found
similar treatment outcomes (P C 0.208)
between besifloxacin-treated patients (n = 142)
and those treated with moxifloxacin (n = 85),
although the results were confounded by
inclusion of other topical antibacterials in the
therapeutic regimen for some patients [69]. The
frequency and duration of besifloxacin and
moxifloxacin use varied but did not differ,
with a median duration of 15 days for both
treatment groups and a final dosing frequency
of 4 or more times daily for the majority of
patients. Both treatment groups had high rates
of physician-assessed bacterial eradication
(95.8% besifloxacin vs. 91.8% moxifloxacin).
Evident corneal scarring was noted in 23.2% of
besifloxacin-treated patients and 29.4% of
moxifloxacin-treated patients and corneal
neovascularization in less than 2% of patients
in either treatment group.
Animal studies provide further evidence that
besifloxacin has great potential as a treatment
for bacterial keratitis, especially for infections
caused by resistant organisms. In a rabbit model
of MRSA keratitis, treatment with besifloxacin
0.6%—early treatment (starting 10 h
post-infection) or late treatment (starting 16 h
post-infection)—resulted in greater reduction in
the number of MRSA in corneas than with
gatifloxacin 0.3% or moxifloxacin 0.5%
(P\0.01 for early treatment; P\0.001 for late
treatment) [70, 71]. Besifloxacin has also been
found more effective (P\0.05) than
gatifloxacin and moxifloxacin in reducing
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bacterial loads in rabbit corneas infected with a
resistant strain of P. aeruginosa [72].
Antibacterial Prophylaxis for Surgery
No topical antibiotic is currently approved for
prophylactic use in ocular surgery. Given the
low rate of postoperative endophthalmitis [73,
74], prospective studies of topical antibiotic
prophylaxis would require extremely large
study populations. Nevertheless, use of topical
antibiotics—particularly fourth-generation
FQs—as surgical prophylaxis is considered a
standard of care [75, 76]. Retrospective studies
suggest that perioperative use of
fourth-generation FQs such as moxifloxacin or
gatifloxacin is associated with low rates of
endophthalmitis after cataract surgery [76, 77].
Human and animal data from previously
mentioned pharmacokinetic studies suggests
that intraocular penetration of FQs, in general,
is minimal [49, 51–53]. Since topical
administration of current FQs cannot achieve
high aqueous humor drug concentrations, an
appropriate goal for topical antibiotics in
surgical prophylaxis is the reduction of the
number of pathogens on the ocular surface.
Indeed, the normal microflora on the eyelids
and conjunctival sac is the main source of the
bacteria associated with endophthalmitis, the
predominant causative organisms being
Gram-positive species, most commonly CoNS
(S. epidermidis) [78, 79].
Bucci et al. [80] randomized 67 cataract
surgery patients to receive besifloxacin or
moxifloxacin before surgery to compare the
FQs’ antibacterial efficacy. Patients instilled
study drug four times a day for 3 days in the
surgical eye and 1 h before surgery in the
nonsurgical fellow eye, and bacterial load was
assessed at the time of surgery. While both
agents reduced the bacterial load on the lid
margin when administered four times daily for
3 days (P B 0.019), only besifloxacin reduced
the lid colony counts within 1 h of instilling a
single drop to nonsurgical eyes (P = 0.039).
In vitro susceptibility testing of baseline
isolates recovered from lid margins and
conjunctiva of these patients shows that
besifloxacin had greater activity for CoNS than
vancomycin (MIC90: 0.5 vs. 2 lg/mL) and an
eightfold lower (better) MIC90 for MRSE than
moxifloxacin. These data, taken together with
the lack of postoperative infections reported
with besifloxacin use in the surgical setting
[81–85], suggest that besifloxacin may
effectively reduce ocular surface flora prior to
or after surgery.
Bacterial Lid Disorders
Besifloxacin ophthalmic suspension 0.6% has
been investigated for the treatment of acute
blepharitis and congenital nasolacrimal duct
obstruction (NLDO) with infection in two small
pilot studies. John et al. compared twice daily
besifloxacin 0.6% and erythromycin
ophthalmic ointment 0.5% in a randomized
study of 30 patients with acute symptomatic
anterior (with or without posterior) blepharitis
[86]. While all patients experienced improved
clinical signs (P\0.05 for both groups) and
symptoms (P\0.005 for both groups) following
two weeks of antibiotic treatment alongside lid
hygiene measures, the besifloxacin group
showed a greater reduction in bacterial loads.
Of the 13 besifloxacin-treated Staphylococcus
isolates (including 5 multidrug resistant
organisms), 6 showed no growth
post-treatment and 7 showed limited growth
of S. epidermidis. In contrast, six of the
erythromycin-treated isolates demonstrated
increased growth of organisms after treatment.
To compare the use of besifloxacin for the
treatment of congenital NLDO with infection
with trimethoprim/polymyxin (Polytrim,
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Allergan, Irvine, CA, USA), Tu et al. [87, 88]
randomized 24 children aged 1–12 months with
diagnosed NLDO with infection. Dosed three
times a day for 10 days, besifloxacin was found
to be as effective as trimethoprim/polymyxin in
treating the condition, with success rates of
88% (8/9) and 91% (10/11), respectively. Only
one patient in each treatment group suffered
recurrent infection.
Safety Profile
Topical ocular administration of besifloxacin
achieves high ocular surface concentrations
with negligible levels in plasma [43], creating
the potential for high therapeutic availability
and effectiveness with a minimal risk of
systemic side effects. Indeed, besifloxacin
demonstrated favorable ocular safety and
tolerability in clinical trials of conjunctivitis
with besifloxacin administered both three times
daily for 5 days and twice daily for 3 days
(Table 3), with rare nonocular side effects [59,
89]. Most adverse events in these studies were
mild or moderate in severity.
In addition, besifloxacin was well-tolerated
by the pediatric patients in the besifloxacin
clinical trials dosed three times daily for 5 days
(N = 815), with similarly low incidences of
ocular adverse events found in all treatment
groups (besifloxacin, moxifloxacin, and vehicle)
[61]. The most commonly reported adverse
events in besifloxacin-treated eyes from
pediatric patients were conjunctivitis (2.9%),
bacterial conjunctivitis (2.1%), and eye pain
(1.8%); headache, the only nonocular adverse
event reported in more than 1% of patients,
occurred in 1–2% of patients in each treatment
group.
More recently, Malhotra et al. [90] examined
the safety of besifloxacin used 3 times daily for
7 days—the FDA-established recommended
dosing regimen—in 514 patients with bacterial
conjunctivitis in a randomized, multicenter,
vehicle-controlled, parallel-group study. The
rates of ocular treatment-emergent adverse
events were similar for besifloxacin-treated and
vehicle-treated patients (4.9% vs. 6.5%,
P = 0.5362). Only 1.2% of besifloxacin-treated
patients and 2.9% of vehicle-treated patients
reported ocular events considered at least
possibly related to treatment, and almost all
ocular events were mild or moderate and
self-limited. No serious nonocular events were
reported; of a total of 16 nonocular events (10
in besifloxacin group and 6 in vehicle group),
only one event of self-limited dysgeusia in the
besifloxacin group was considered definitely
related to treatment. The results, overall,
indicate that besifloxacin ophthalmic
suspension 0.6% is safe when used three times
daily for seven days.
Until very recently, there was no human data
on the safety of besifloxacin in the treatment of
bacterial keratitis. As indicated earlier,
Schechter et al. [69] evaluated the safety as
well as the efficacy of besifloxacin in the
treatment of 142 patients with bacterial
keratitis in the retrospective multicenter study.
Only one ocular adverse event of mild punctate
keratitis was reported, which resolved without
scarring or neovascularization.
The safety of besifloxacin for antibacterial
prophylaxis in ocular surgery has been studied
to a greater extent. A retrospective chart review
of 801 laser-assisted in situ keratomileusis
(LASIK) cases found that perioperative use of
besifloxacin (n = 534; 2–4 times daily, mean
treatment duration: 8.6 days) and moxifloxacin
ophthalmic solution 0.5% (n = 267; 4 or more
times daily, mean treatment duration: 8.0 days)
in patients undergoing LASIK surgery was not
associated with any adverse drug reaction [83].
Similarly, a recent prospective, multisite, LASIK
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safety surveillance study by Majmudar and
Clinch [85] suggested besifloxacin appears safe
for surgical prophylaxis; among the 456 study
eyes (besifloxacin: n = 344; moxifloxacin,
n = 112), no treatment-emergent adverse
events were reported.
However, problems with the prophylactic
use of besifloxacin in the surgical setting have
been reported under particular circumstances.
Talamo et al. [91] reported delayed epithelial
closure (5 to 13 days, with an average of
8.8 days) and delayed visual recovery in a case
series of 4 patients (7 eyes) treated with
besifloxacin 0.6% instilled underneath a
bandage contact lens (BCL) placed at the
conclusion of photorefractive keratectomy
(PRK) [91]. These adverse reactions were
attributed by the authors to potential toxic
effects of DuraSite or the preservative
benzalkonium chloride 0.01% on exposed
corneal stroma, especially when drug contact
time is prolonged. Consistent with this premise,
a joint alert issued by the American Society of
Cataract and Refractive Surgery (ASCRS) Cornea
and Refractive Surgery Committees in 2013
recommended withholding topical ophthalmic
medications with advanced vehicles
immediately prior to or intraoperatively
during LASIK or PRK while the stromal bed is
exposed [92].
To date, there has been no other evidence in
the literature for such adverse events with the
besifloxacin formulation. Donnenfeld et al. [84]
evaluated the effect of besifloxacin 0.6% or
moxifloxacin 0.5% (Vigamox) on epithelial
wound healing following PRK in a prospective,
contralateral eye, double-masked, multicenter
study. A total of 80 eyes (40 patients) were
randomized to either besifloxacin or
moxifloxacin administered 3 times daily after
Table 3 Treatment-emergent ocular AEs with C1% incidence (unless speciﬁed otherwise) of study eyes in any treatment
group from besiﬂoxacin clinical trials















191 146 81 – 12 14
Number of eyes
with C1 AE
139 (11.7) 101 (16.4) 54 (9.3) 0.006 12 (5.3) 12 (5.1)
Blurred vision 25 (2.1) 24 (3.9) 3 (0.5) 0.032 – –
Eye irritation 17 (1.4) 18 (2.9) 8 (1.4) 0.046 – –
Eye pain 22 (1.8) 11 (1.8) 7 (1.2) [0.99 – –
Conjunctivitis 14 (1.2) 15 (2.4) 5 (0.9) 0.049 5 (2.2) 5 (2.1)
Eye pruritus 13 (1.1) 10 (1.6) 2 (0.3) 0.38 – –
Conjunctivitis,
bacterial
7 (0.6) 9 (1.5) 2 (0.3) 0.068 2 (0.9) 1 (0.4)
Values expressed as n (%)
AE adverse event
* Pooled data from six clinical and Phase I safety studies [89]
** No signiﬁcant difference between treatment groups; all P values (Fisher’s exact test) were[0.2 [59]
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the BCL was placed and until the cornea was
healed. The two groups demonstrated no
difference (P = 0.763) in epithelial wound
healing, with mean time to complete
epithelial closure 80.9 ± 11.8 h (range
3–5 days) for besifloxacin-treated eyes and
82.4 ± 12.1 h (range 3–5 days) for the
moxifloxacin-treated eyes. These results are
consistent with findings in animal models of
corneal epithelial defects that neither DuraSite
nor besifloxacin negatively affects corneal
reepithelialization [93, 94].
Concerns have also emerged in regards to
suture-less clear corneal surgery, where it has
been suggested that a leaking wound could give
the DuraSite vehicle entry to the anterior
chamber, block the trabecular meshwork, and
cause significant anterior chamber toxicity [95,
96]. Studies in patients undergoing routine,
uncomplicated, suture-less cataract surgery,
however, have thus far produced no clinical
evidence that prophylactic use of besifloxacin is
associated with any significant safety concerns.
A randomized, parallel-group,
investigator-masked study of 58 patients
undergoing suture-less clear cornea surgery
reported no adverse events with either
besifloxacin or moxifloxacin used
prophylactically (both administered 4 times
daily starting 3 days prior to surgery and
continued for 7 days postoperatively) [81].
Similarly, Parekh et al. [82] found no evidence
of adverse drug reactions following besifloxacin
or moxifloxacin prophylaxis in a retrospective
chart review of more than 700 consecutive cases
of routine cataract surgery obtained from nine
clinical centers in the US (besifloxacin: n = 493,
89% suture-less; moxifloxacin: n = 253, 78%
suture-less) [82]. Finally, in a prospective,
multisite, cataract surgery surveillance study of
485 eyes (besifloxacin: n = 333; moxifloxacin:
n = 152) conducted by Majmudar and Clinch
[85], only 1 treatment-emergent adverse event
(mild hypersensitivity or allergic reaction) was
reported in a besifloxacin case, and this resolved
after discontinuation of medication.
CONCLUSIONS
Besifloxacin is a novel topical
C8-chlorofluoroquinolone with potent,
broad-spectrum antibacterial activity and a
favorable pharmacokinetic profile that
together supports its use in the empirical
treatment of bacterial infection at the ocular
surface. Besifloxacin has been established as an
effective and safe treatment for bacterial
conjunctivitis, while further investigations are
needed to assess its safety and efficacy in
bacterial keratitis, antimicrobial prophylaxis in
ocular surgery, and for the treatment of
bacterial lid disorders. Compared with other
topical FQs, besifloxacin ophthalmic
suspension offers several potential therapeutic
advantages, including higher ocular surface
drug concentrations, longer ocular surface
exposure times, and greater efficacy against
FQ-resistant ocular pathogens, including MRSA
and MRSE.
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